about
Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension.Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantationThe clinical use of HVPG measurements in chronic liver disease.Acute variceal bleeding.Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients.Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension.Early use of TIPS in patients with cirrhosis and variceal bleeding.Acute and long-term effects of inhaled iloprost in portopulmonary hypertension.Characterization of γδ T cell subsets in organ transplantation.Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy.Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers.A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures.Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers.Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study.Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction.Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis.Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome.Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis.Home Exercise Training Improves Exercise Capacity in Cirrhosis Patients: Role of Exercise Adherence.Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.A MELD-based model to determine risk of mortality among patients with acute variceal bleeding.The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis.Portal Hypertension–Related Complications After Acute Portal Vein Thrombosis: Impact of Early AnticoagulationSelective arterial embolization for life threatening hemobilia after transjugular intrahepatic portosystemic shunt placementPersistent hypertransaminasemia as the presenting feature of celiac diseaseRecombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trialImpact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary CareClassifying varices in cirrhosis: Who's got the best look?Editorial: is there a causal link between non-selective beta blockers and portal vein thrombosis in cirrhosis?Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failureFaecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids
P50
Q34631908-08AE5E79-B09A-45BC-A1E9-F3A08303D225Q35640630-B2234BD9-25EC-41C4-8DF7-A86E33788897Q37590666-78D57202-D5D8-46DC-8089-98685C2A14C1Q37996901-5FE39F95-8D24-44D0-8BC5-D342AC62FFB2Q39416636-F836249A-B9C1-4533-8CE3-8FF8E297D37FQ40100867-448B37DD-2C4B-494D-B501-0EB4BD28456BQ42865765-BB99FEFD-B5B7-480D-A88D-D02DBE456C9BQ43007310-2895B2A2-B4D6-4F2A-A512-711E48C7C1FBQ43139838-D4C5ADD9-0098-40E8-9B0F-1A603E497274Q44087742-96B22AF2-6631-4CB7-9911-47BDC8390490Q44192825-4FFC5092-31CE-40E7-BFC6-CF29F2B24852Q44261204-F6DCF534-A464-4417-9F1D-8B0CAA8C4B9EQ44415194-25F57697-B9E2-459F-AD5F-EAF907128751Q44583408-3AC5443C-E691-4F23-8396-A877A03EEBA9Q44591514-2A712714-C05B-421B-AE4E-FC668EF1FB2AQ44743116-BC651A52-88B9-4B73-9A22-06BEA9F98998Q46126097-FF97F8F0-FB3B-4B08-AF13-E46EF0F35B89Q46213897-E29ECF88-4691-41A5-A6DE-6C4B6C7266A2Q46703498-AB788CD9-7E9B-417B-8033-84FD01381970Q46865799-5A2F7131-5C92-4CDC-ABB6-2C75B52D17F0Q46865801-45E7C577-2E1A-4C09-9B4C-9B37E00E99C9Q47192745-A1BC0B67-9EF2-4BD8-A035-E58CA9FF1245Q47279523-917CE05D-1FA9-477A-AE8E-59202848CA54Q50484457-94FCC1E8-7C17-4909-9F4C-E3657C4D3687Q53153940-AAD1B570-4B96-45CF-9595-77A17E3FDAA0Q62616236-B75C9543-7782-4EF6-B8B4-BCA1CC4A25F5Q73521148-42C39FBF-BE29-4FCD-B16E-B558F1C4C49AQ77319047-4FE6DA99-9978-440C-AA3D-223D20F70159Q80853264-0D4D5E6F-CB6C-484C-8EC8-37964CB89694Q90580674-71D0D6DA-02C0-4FE6-BAC3-10006D094CC0Q91628447-1F539C76-8A74-40C9-A1DE-EA989CB75168Q91965727-B69F59BC-C78D-4456-94C4-B4171DFA188EQ92066189-601D3B67-21AA-45F5-B5FC-CD97EE6488F0Q92666470-62AD8639-8781-4DD5-832B-234918DE985F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juan G. Abraldes
@ast
Juan G. Abraldes
@en
Juan G. Abraldes
@es
Juan G. Abraldes
@nl
Juan G. Abraldes
@sl
type
label
Juan G. Abraldes
@ast
Juan G. Abraldes
@en
Juan G. Abraldes
@es
Juan G. Abraldes
@nl
Juan G. Abraldes
@sl
altLabel
Gonzalez-Abraldes J
@en
prefLabel
Juan G. Abraldes
@ast
Juan G. Abraldes
@en
Juan G. Abraldes
@es
Juan G. Abraldes
@nl
Juan G. Abraldes
@sl
P106
P1153
6505951638
6603014982
P21
P31
P496
0000-0003-3421-937X